Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.13 | N/A | -27.93% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.13 | N/A | -27.93% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach due to the lack of specific guidance. They emphasized their commitment to ongoing projects.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on its ongoing projects and pipeline developments.
PTC Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by nearly 3% following the earnings report, possibly due to market optimism about future projects and pipeline developments. The lack of revenue details and guidance leaves some uncertainty about the company's financial outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Aug 1, 2022